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Tasks
Task 1. Determine the methylation profile of candidate tumor-suppressor genes in CML patients treated with Imatinib, months 1-24: a. Identify in the leukemia database all patients treated with Imatinib at MDACC for whom follow-up of over 1 year is available (month 1) b. Collect paraffin-embedded pre-treated bone marrow biopsies on all patients (projected 400 patients, 40 cut/month, months 1-10) c. Extract DNA from paraffin cuts (start month 1 -ongoing until all samples collected, months 1-10) d. Bisulfite treatment and PCR-based methylation analysis for all the genes (months 2-20) e. Statistical analysis of the collected data (months [21] [22] f. Validation of the results on prospectively collected samples (months 23-36) Task 2. Conduct a clinical trial of 5-aza-deoxycytidine followed by Imatinib in patients with CML resistant to, or less likely to respond to Imatinib. a. Treat initial 6 patients for toxicity analysis of the combination (months 1-2) b. Enroll patients on the phase II study (projected 3-5/month, months c. Continue subsequent cycles and follow-up of the patients (months [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Task 3. Determine the methylation and expression status of candidate tumor-suppressor genes after treatment with 5-aza-deoxycytidine and correlate these values with subsequent responses to Imatinib. a. Collect samples before and after treatment (months b. Analyze samples for methylation (months 13-36) c. Analyze samples for gene expression (months d. Statistical analysis of the collected data (months 32-36)
Progress on Task 1:
We have obtained samples from 200 patients with CML at various phases with outcome data and have extracted DNA from them (Tasks 1a-1c). A pilot study of multiple genes has identified a panel of genes (P15, LINE, PGRA, PGRB, CDH13, NOR1, NPM2, DPYS, RIL) that are informative for DNA methylation in CML. We are proceeding with bisulfite/pyrosequencing analysis of all these samples (Task 1d) and statistical analysis (Task 1e). At the time of this writing, we have a complete data set on 130 cases, and have run preliminary analyses of the clinical correlations. More in depth analyses are ongoing. Highlights of our findings are:
Mean methylation (%) and frequency of methylation (% of cases with methylation >15) CP: Chronic phase, AP: Accelerated phase, BC: Blast crisis, All: All patients. In each cell, the first value is R and the second is p. Positive correlations in each stage are present, suggesting that a hypermethylator phenotype is present (CIMP). The next figure illustrates this by providing a heat map of all methylation data by stage.
In this map, methylation <15 is in green, methylation 15-30 in yellow and >30 in red.
Methylation increases with increasing stage of CML Methylation was generally independent of age or gender. We next examined methylation vs. stage of CML. Because methylation is concordant, we derived a methylation index for each case by calculating z-scores and deriving a mean z-score/patient. This was true for all genes (excluding abl) or for a subset of only 3 genes (NPM2, NOR1 and DPYS). 
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The above figure shows z-scores for all genes in CML cases grouped by stage. The differences between each stage are statistically significant. The differences remain significant when a group of only 3 genes is considered (below). The next figure shows scatter plots of NOR1 methylation by stage and imatinib resistance. 
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We also looked at methylation index and imatinib resistance. There we strong associations between the index of NOR1, NPM2 and DPYS with imatinib resistance (see below). 
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Thus, to summarize progress for this task, we have shown that methylation is frequently abnormal in CML, that it increases with disease stage and that it increases in cases resistant to imatinib, providing rationale for incorporating methylation inhibitors in the treatment of CML.
Progress on tasks 2 and 3
At the outset of the grant, tasks 2 and 3 were modified slightly to include only analysis of samples collected as part of the clinical trials outlined.
A clinical trial of single agent decitabine was performed in Imatinib-resistant CML. This trial included correlative studies funded by this grant and it was recently published 1 . The abstract follows:
Purpose. To determine the activity of decitabine, a DNA methylation inhibitor, in imatinib refractory or intolerant chronic myelogenous leukemia (CML). Patients and methods. Thirty five patients were enrolled in this phase II study (12 in chronic phase [CP] , 17 in accelerated phase [AP] and 6 in blastic phase [BP] ). Decitabine was administered at 15 mg/m 2 IV over one hour daily, 5 days a week for two weeks. DNA methylation was measured using a LINE1 bisulfite/pyrosequencing assay. Results. Complete hematologic responses were seen in 12 patients (34%) and partial hematologic responses in 7 patients (20%), for an overall hematologic response rate of 54% (83% in CP, 41% in AP and 34% in BP). Major cytogenetic responses were observed in 6 patients (17%), and minor cytogenetic responses were seen in 10 patients (29%) for an overall cytogenetic response rate of 46%. Median response duration was 3.5 months (range 2-13+ months). Myelosuppression was the major side-effect, with neutropenic fever in 28/124 (23%) courses of therapy. LINE1 methylation decreased from 71.3+/-1.4% (mean+/-SEM) to 60.7+/-1.4% after 1 week, 50.9+/-2.4 after 2 weeks and returned to 66.5+/-2.7% at recovery of counts (median, 46 days). LINE1 methylation at the end of week 1 did not correlate with subsequent responses. However, at day 12, the absolute decrease in methylation was 14.5+/-3.0% vs. 26.8+/-2.7% in responders vs. nonresponders (p=0.007). Conclusions. Decitabine induces hypomethylation and has clinical activity in imatinib refractory CML. We hypothesize that the inverse correlation between hypomethylation and response is due to a cell death mechanism of response, whereby resistant cells can withstand more hypomethylation.
Highlights of the correlative studies were:
(1) Methylation decreases in treated patients in a dose-dependent way:
(2) Methylation decreases more in non-responders at 10 days, consistent with a cell death mechanism of action of the drug, whereby non-responders have hypomethylation but do not die.
Another study was initiated that combined Imatinib with Decitabine. This study has accrued well. The data are now submitted for publication. A summary of the data follow.
Abstract
Purpose: To determine the activity of decitabine, a DNA methylation inhibitor, in combination with imatinib mesylate (imatinib) in patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) or blastic phase (BP).
Patients and Methods:
Patients received decitabine at 15mg/m 2 intravenously daily, 5 days a week for 2 weeks, and imatinib at 600mg orally daily. Global DNA methylation was measured using a LINE bisulfite/pyrosequencing assay. Results: Twenty-eight patients were enrolled (18 in AP, 10 in BP, and 25 with previous imatinib resistance). A total of 91 cycles (median 2.5 cycles per patient) was administered. Complete hematologic responses, partial hematologic responses, and hematologic improvement were observed in 9 (32%), 1 (4%) and 2 (7%) patients. Major and minor cytogenetic responses were observed in 5 (18%) and 3 (11%) patients. The hematologic response rate was higher in patients without BCR-ABL kinase mutations (1 of 7, 14%) than in patients with mutations (10 of 19, 53%). Median duration of hematologic response was 18 (range 4 to 107+) weeks. Myelosuppression was the major adverse effect, with neutropenic fever in 9 patients (32%). LINE methylation decreased from 71.6%±0.9% (mean ± standard error of the mean) to 60.4%±2.0% on day 5, 60.5%±1.8% on day 12, and returned to 68.8%±1.4% at peripheral blood recovery. Decrease in LINE methylation trended to be greater in non-responders than responders on day 5 and day 12. Conclusion: Combination therapy of decitabine with imatinib is well tolerated and active in advanced phase CML, particularly in patients without BCR-ABL kinase mutations.
The figure above shows survival in this study by response to the combination. The figure above shows global methylation dynamics after the combination of DAC+imatinib in responders vs. non-responders.
Key research accomplishments
• Determined that methylation increases with CML progression, and is increased further at Imatinib resistance • Analyzed samples from patients treated with decitabine in a phase 1 study and showed dose dependent hypomethylation in-vivo • Analyzed samples from patients with imatinib resistant CML treated with decitabine, confirmed hypomethylation in-vivo, found correlations between degree of methylation at 10 days after therapy and lack of response and found similar hypomethylation at the development of resistance to decitabine in CML, suggesting a non-pharmacologic mechanism of resistance • Analyzed samples from patients with imatinib resistant CML treated with a combination of imatinib and decitabine and confirmed the above findings
Reportable outcomes
Manuscript published Issa,J.P., Gharibyan,V., Cortes,J., Jelinek,J., Morris,G., Verstovsek,S., Talpaz,M., GarciaManero,G. & Kantarjian,H.M. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23, 3948-3956 (2005) . 
